Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is 5,738.37 MM.
- The operating income for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is 2,265.42 MM.
- The net income for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is -863.92 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 5,738.37 | 2,265.42 | -863.92 |
2025-03-31 | 5,043.13 | 2,015.84 | -847.23 |
2024-12-31 | 4,485.12 | 1,831.85 | -885.33 |
2024-09-30 | 3,792.70 | 1,401.33 | -914.91 |
2024-06-30 | 2,908.84 | 1,140.90 | -1,146.77 |
2024-03-31 | 2,389.07 | 600.55 | -1,530.39 |
2023-12-31 | 2,209.59 | 298.73 | -1,797.55 |
2023-09-30 | 1,919.21 | -675.97 | -1,096.65 |
2023-06-30 | 2,241.98 | -594.63 | -953.06 |
2023-03-31 | 2,594.97 | -239.06 | -614.72 |
2022-12-31 | 2,919.32 | -12.39 | -325.04 |
2022-09-30 | 2,702.85 | -24.80 | -109.66 |
2022-06-30 | 2,882.23 | 239.12 | 52.10 |
2022-03-31 | 2,750.33 | 318.31 | 33.33 |
2021-12-31 | 2,844.21 | 402.57 | 140.26 |
2021-09-30 | 3,046.66 | 548.74 | 270.58 |
2021-06-30 | 2,824.38 | 459.09 | 59.68 |
2021-03-31 | 2,955.53 | 629.53 | 184.19 |
2020-12-31 | 2,627.21 | 447.42 | -48.98 |
2020-09-30 | 2,839.12 | 697.94 | 212.48 |
2020-06-30 | |||
2020-03-31 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | -0.40 | |
2024-09-30 | -0.46 | -0.46 |
2024-06-30 | -0.52 | -0.52 |
2024-03-31 | -0.64 | -0.64 |
2023-12-31 | -0.67 | -0.67 |
2023-09-30 | -0.30 | -0.30 |
2023-06-30 | -0.31 | -0.31 |
2023-03-31 | -0.25 | -0.25 |
2022-12-31 | -0.17 | -0.17 |
2022-09-30 | -0.06 | |
2022-06-30 | 0.03 | 0.03 |
2022-03-31 | 0.02 | 0.02 |
2021-12-31 | 0.07 | 0.07 |
2021-09-30 | 0.14 | |
2021-06-30 | 0.03 | 0.03 |
2021-03-31 | 0.10 | 0.10 |
2020-12-31 | -0.03 | -0.03 |
2020-09-30 | 0.11 | |
2020-06-30 | 0.22 | 0.22 |
2020-03-31 | 0.14 | 0.14 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is 862.67 MM.
- The cash from investing activities for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is -459.21 MM.
- The cash from financing activities for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is -1,536.11 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 862.67 | -459.21 | -1,536.11 |
2025-03-31 | 959.45 | -756.66 | -1,130.26 |
2024-12-31 | 396.21 | -699.32 | -928.64 |
2024-09-30 | 456.18 | -845.12 | -717.74 |
2024-06-30 | -173.60 | -1,073.97 | -705.99 |
2024-03-31 | -363.54 | -1,045.02 | -673.80 |
2023-12-31 | -773.41 | -933.88 | 2,720.51 |
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | 132.55 | -1,269.61 | -110.15 |
2022-09-30 | -61.76 | -1,143.01 | 3.58 |
2022-06-30 | 641.47 | -938.97 | -503.89 |
2022-03-31 | 653.37 | -521.85 | -674.52 |
2021-12-31 | 546.41 | -406.83 | -612.91 |
2021-09-30 | 346.03 | -339.21 | -640.06 |
2021-06-30 | -214.64 | -58.41 | 4.96 |
2021-03-31 | -332.73 | -494.64 | 2,302.64 |
2020-12-31 | -227.12 | -520.32 | 3,145.00 |
2020-09-30 | 302.52 | -564.05 | 2,818.46 |
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 | ||
2020-03-31 |
Management Effectiveness
- The roa for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is -0.09.
- The roe for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is -0.52.
- The roic for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is -0.12.
- The croic for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is -0.00.
- The ocroic for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is 0.13.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | -0.09 | -0.52 | -0.12 | -0.00 | 0.13 |
2025-03-31 | -0.19 | -0.55 | -0.35 | -0.07 | 0.47 |
2024-12-31 | -0.22 | -1.03 | -0.33 | -0.05 | 0.08 |
2024-09-30 | -0.22 | -0.53 | -0.38 | -0.20 | -0.03 |
2024-06-30 | -0.26 | -0.62 | -0.45 | -0.22 | -0.06 |
2024-03-31 | -0.39 | -2.88 | -0.44 | 0.29 | -0.03 |
2023-12-31 | -0.17 | -1.00 | -0.16 | 0.00 | 0.00 |
2023-09-30 | -0.14 | -0.88 | -0.13 | 0.00 | 0.00 |
2023-06-30 | -0.09 | -0.88 | -0.12 | 0.00 | 0.00 |
2023-03-31 | -0.04 | -0.57 | -0.07 | -0.20 | -0.00 |
2022-12-31 | -0.08 | -0.02 | -0.27 | -0.01 | |
2022-09-30 | 0.01 | -0.08 | -0.02 | -0.25 | -0.01 |
2022-06-30 | 0.01 | 0.04 | 0.01 | -0.18 | 0.14 |
2022-03-31 | 0.02 | 0.03 | 0.01 | -0.12 | 0.14 |
2021-12-31 | 0.04 | 0.25 | 0.13 | ||
2021-09-30 | 0.04 | 0.19 | 0.05 | -0.11 | -0.06 |
2021-06-30 | 0.01 | 0.05 | 0.01 | -0.06 | -0.08 |
2021-03-31 | 0.05 | 0.16 | 0.03 | 0.26 | -0.08 |
2020-12-31 | -0.02 | -0.04 | -0.01 | 0.42 | -0.04 |
2020-09-30 | 0.13 | 0.34 | 0.06 | 0.43 | 0.05 |
2020-06-30 | 0.18 | 0.42 | 0.09 | 0.53 | 0.03 |
2020-03-31 | 0.11 | 0.28 | 0.09 | 0.30 | 0.15 |
Gross Margins
- The gross margin for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is 0.41.
- The net margin for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is -0.17.
- The operating margin for Neimeth International Pharmaceuticals Plc as of 30 June 2025 is 0.40.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | 0.41 | -0.17 | 0.40 |
2025-03-31 | 0.44 | -0.38 | 0.21 |
2024-12-31 | 0.42 | -0.52 | 0.08 |
2024-09-30 | 0.46 | -0.76 | 0.03 |
2024-06-30 | 0.46 | -1.09 | -0.19 |
2024-03-31 | 0.33 | -1.17 | -0.28 |
2023-12-31 | 0.28 | -0.57 | -0.35 |
2023-09-30 | 0.28 | -0.43 | -0.27 |
2023-06-30 | 0.28 | -0.43 | -0.27 |
2023-03-31 | 0.37 | -0.24 | -0.09 |
2022-12-31 | 0.40 | -0.04 | -0.01 |
2022-09-30 | 0.42 | -0.04 | -0.01 |
2022-06-30 | 0.47 | 0.02 | 0.08 |
2022-03-31 | 0.47 | 0.01 | 0.12 |
2021-12-31 | 1.00 | 0.05 | 0.14 |
2021-09-30 | 0.47 | 0.09 | 0.18 |
2021-06-30 | 0.47 | 0.02 | 0.12 |
2021-03-31 | 0.50 | 0.06 | 0.17 |
2020-12-31 | 0.49 | -0.02 | 0.13 |
2020-09-30 | 0.53 | 0.12 | 0.23 |
2020-06-30 | 0.55 | 0.14 | 0.26 |
2020-03-31 | 0.50 | 0.11 | 0.20 |
Identifiers and Descriptors
Central Index Key (CIK) |